

Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C

Masayuki Kurosaki¹, Naoki Hiramatsu², Minoru Sakamoto³, Yoshiyuki Suzuki⁴, Manabu Iwasaki⁵, Akihiro Tamori⁶, Kentaro Matsuura⁷, Sei Kakinuma⁸, Fuminaka Sugauchi⁹, Naoya Sakamoto⁸, Mina Nakagawa⁸, Namiki Izumi^{1,*}

¹Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan; ²Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan; ³First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan; ⁴Department of Hepatology, Toranomon Hospital, Tokyo, Japan; ⁵Department of Computer and Information Science, Seikei University, Tokyo, Japan; ⁶Department of Hepatology, Osaka City University Medical School, Osaka, Japan; ⁷Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ⁸Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan; ⁹Department of Gastroenterology, Nagoya Koseiin Medical Welfare Center, Nagoya, Japan

Background & Aims: Assessment of the risk of hepatocellular carcinoma (HCC) development is essential for formulating personalized surveillance or antiviral treatment plan for chronic hepatitis C. We aimed to build a simple model for the identification of patients at high risk of developing HCC.

Methods: Chronic hepatitis C patients followed for at least 5 years (n = 1003) were analyzed by data mining to build a predictive model for HCC development. The model was externally validated using a cohort of 1072 patients (472 with sustained virological response (SVR) and 600 with nonSVR to PEG-interferon plus ribavirin therapy).

Results: On the basis of factors such as age, platelet, albumin, and aspartate aminotransferase, the HCC risk prediction model identified subgroups with high-, intermediate-, and low-risk of HCC with a 5-year HCC development rate of 20.9%, 6.3–7.3%, and 0–1.5%, respectively. The reproducibility of the model was confirmed through external validation ($r^2 = 0.981$). The 10-year HCC development rate was also significantly higher in the high- and intermediate-risk group than in the low-risk group (24.5% vs. 4.8%; $p < 0.0001$). In the high- and intermediate-risk group, the incidence of HCC development was significantly reduced in patients with SVR compared to those with nonSVR (5-year rate, 9.5% vs. 4.5%; $p = 0.040$).

Conclusions: The HCC risk prediction model uses simple and readily available factors and identifies patients at a high risk of HCC development. The model allows physicians to identify patients requiring HCC surveillance and those who benefit from IFN therapy to prevent HCC.

Keywords: Decision tree; Prediction; Pegylated interferon; Ribavirin; Risk.
Received 27 May 2011; received in revised form 8 August 2011; accepted 4 September 2011; available online 23 October 2011

* Corresponding author. Address: Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan. Tel.: +81 422 32 3111; fax: +81 422 32 9551.

E-mail address: nizumi@musashino.jrc.or.jp (N. Izumi).



© 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide [1] and its incidence is increasing in many countries [2]. Chronic viral hepatitis is responsible for 80% of all HCC cases [2]. The need to conduct HCC surveillance should be determined according to the risk of HCC development because this surveillance is cost-effective only in populations with an annualized cancer development rate of $\geq 1.5\%$ [3]. The annualized rate of developing HCC from type C liver cirrhosis is 2–8% [4–6], indicating that this population with type C liver cirrhosis needs surveillance. However, the annualized rate of HCC development is $< 1.5\%$ in patients with chronic hepatitis C but without cirrhosis and the benefit of surveillance for all patients with chronic hepatitis has not yet been established [3]. HCC surveillance may be needed for patients with advanced fibrosis because the risk of HCC development increases in parallel with the progression of liver fibrosis [7,8]. Liver biopsy is the most accurate means of diagnosing fibrosis, but a single liver biopsy cannot indicate long-term prognosis because liver fibrosis progresses over time. Serial liver biopsies are not feasible because of the procedure's invasiveness. Moreover, factors other than fibrosis, such as advanced age, obesity, sex, lower albumin, and low platelet counts, also contribute to the development of HCC from chronic hepatitis C [8–11]. Therefore, these factors must be considered while assessing the risk of HCC development.

A meta-analysis of controlled trials [12] has shown that interferon (IFN) therapy reduced the rate of HCC development in patients with type C liver cirrhosis. However, there was a marked heterogeneity in the magnitude of the prevention effect

of IFN on HCC development among the studies, probably due to the large differences in the baseline rate of HCC development among the different trials [12]. Whether the incidence of HCC development could be reduced in all patients with chronic hepatitis C, especially in those without liver cirrhosis, remains to be elucidated.

Data mining analysis, unlike conventional statistical analysis, is performed in an exploratory manner without considering a predefined hypothesis. Decision tree analysis, the major component of data mining analysis, is used to extract relevant factors from among various factors. These relevant factors are then combined in an orderly sequence to identify rules for predicting the incidence of the target outcome [13]. Data mining analysis has been used to define prognostic factors in various diseases [14–20]. In the field of hepatic diseases, data mining analysis has proven to be a useful tool for predicting early response [21], sustained virological response (SVR) [22–25], relapse [26], and adverse events [27] in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) plus ribavirin (RBV). The findings of data mining analysis are expressed as flowcharts and are therefore easily understood [28] and readily available for clinical use, even by physicians without a detailed understanding of statistics.

In the present study, data mining analysis was used to identify risk factors for HCC development in a cohort of patients with chronic hepatitis C who had been followed for at least 5 years. An HCC risk prediction model was constructed on the basis of simple and generally available tests because the goal was to make the model easy to use in the clinic. The suitability, reproducibility, and generalizability of the results were validated using the data of an external cohort that was independent of the model derivation cohort.

Materials and methods

Patients

The model derivation cohort consisted of 1003 chronic hepatitis C patients without cirrhosis who had a non-sustained virological response (nonSVR) to previous IFN administered at the Musashino Red Cross Hospital and were followed for at least 5 years. Patients who had SVR or those who were followed for less than 5 years were not included. An analytical database on age, body mass index, albumin, aspartate aminotransferase (AST) levels, alanine aminotransferase (ALT) levels, γ -glutamyltransferase (GGT) levels, total bilirubin levels, total cholesterol levels, hemoglobin levels, and platelet count at the start of the observation was created. Histological data such as fibrosis stage, activity grade, or degree of steatosis was not included in the database because the goal of the present study was to make the model on the basis of simple and generally available tests. The patients who developed HCC more than 5 years after the start of the observation were considered not to have developed HCC by the 5-year point because the model was intended to predict HCC development within 5 years. The 1072 chronic hepatitis C patients included in the external validation cohort were treated with PEG-IFN and RBV at the University of Yamanashi, Tokyo Medical and Dental University, Osaka University, Osaka City University, Nagoya City University, or Toranomon Hospital and followed for at least 5 years. Among them, 600 had nonSVR and 472 had SVR. Data from nonSVR patients in this external cohort were used for external validation of the HCC prediction model. To assess the preventive effect of PEG-IFN plus RBV therapy on HCC development, the cumulative HCC development rate was compared between SVR and nonSVR patients in the external validation cohort after stratification by the risk of HCC development as determined by data mining analysis. Informed consent was obtained from each patient. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review committees of all concerned hospitals.

HCC surveillance and diagnosis

HCC surveillance was conducted by performing abdominal ultrasonography every 4–6 months. Contrast-enhanced computer tomography, magnetic resonance imaging, or angiography were performed when abdominal ultrasonography suggested a new lesion suspicious for HCC. Classical HCC was diagnosed for tumors showing vascular enhancement with washout on at least two types of diagnostic imaging. Tumor biopsy was used to diagnose tumors with non-classical imaging findings.

Statistical analysis

The IBM-SPSS Modeler 13 (IBM SPSS Inc., Chicago, IL, USA) was used for decision tree analysis. The statistical methods used have been described previously [21,22,24–27]. In brief, the software searched the analytical database for the factor that most effectively predicted HCC development and for its cutoff value. The patients were divided into two groups according to that predictor. Each divided group was repeatedly assessed and divided according to this 2-choice branching method. Branching was stopped when the number of patients decreased to ≤ 20 to avoid over fitting. Finally, an HCC risk prediction model was created through this analysis. The model classified patients into subgroups with different HCC development rates in a flowchart form. For model validation, nonSVR patients from an external cohort were individually fitted into the model and classified into the subgroups and the HCC development rates of those subgroups were then calculated. The suitability and reproducibility of the model were validated by comparing the subgroup HCC development rates of the model derivation group to those of the validation group.

On univariate analysis, Student's *t*-test was used for continuous variables and Fisher's exact test was used for categorical data. Logistic regression was used for multivariate analysis. A log-rank test for Kaplan–Meier analysis was used to statistically test HCC development rates over time. *p*-Values of <0.05 were considered significant. SPSS Statistics 18 (IBM SPSS Inc.) was used for these analyses.

Results

Univariate and multivariate analysis of factors associated with HCC development

The baseline characteristics of patients are shown in Table 1. The 5-year HCC development rate in the model derivation group was 6.2%, which did not differ significantly from the rate of 6.0% in the nonSVR group of the external cohort, but the rate of 2.0% in the SVR group of the external cohort was significantly lower than that in the model derivation group ($p = 0.0003$) and the nonSVR group of the external cohort ($p = 0.0012$). On univariate analysis, the factors found to be associated with HCC development in the model derivation cohort were age, AST levels, albumin levels, total cholesterol levels, and platelet count. On multivariate analysis, age (odds ratio 1.086), albumin levels (odds ratio 0.248), and platelet count (odds ratio 0.842) were significant predictors of HCC development (Table 2).

HCC risk prediction model by data mining analysis

The results of decision tree analysis are presented in Fig. 1. Age was selected as the first predictor. The 5-year HCC development rate was 3.4% in younger patients (<60 years) and 8.6% in older patients (≥ 60 years). The second predictor for younger patients (<60 years) was platelet count. The HCC development rate was 6.9% in patients with a lower platelet count ($<150 \times 10^9/L$) and 0.8% in patients with a higher count ($\geq 150 \times 10^9/L$). The second predictor for older patients (≥ 60 years) was also platelet count. The HCC development rate was 13.1% in patients with a lower platelet count ($<150 \times 10^9/L$) and 1.8% in patients with a higher count ($\geq 150 \times 10^9/L$). The third predictor was albumin levels,

Research Article

Table 1. Baseline characteristics of patients for model deviation and external validation.

	Model derivation (n = 1003)	External cohort, non-SVR (n = 600)	External cohort, SVR (n = 472)
Sex: Male/Female*	463 (46%)/540 (54%)	306 (51%)/294 (49%)	299 (63%)/173 (37%)
Age (yr)	57.3 (11.1)	55.9 (9.6)	51.4 (10.6)
Body mass index (kg/m ²)	23.5 (3.2)	23.4 (3.3)	23.3 (3.1)
Albumin (g/dl)	4.1 (0.3)	4.0 (0.4)	4.0 (0.3)
AST (IU/L)	64.2 (36.5)	67.3 (43.8)	62.5 (48.3)
ALT (IU/L)	80.6 (55.1)	81.2 (62.3)	88.6 (82.1)
GGT (IU/L)	59.3 (50.5)	67.6 (65.1)	55.7 (71.2)
Total cholesterol (mg/dl)	172.1 (31.5)	168.2 (31.0)	174.3 (33.7)
Platelet (10 ⁹ /L)	154.0 (53.0)	153.7 (53.2)	176.6 (49.7)
Hemoglobin (g/dl)	13.3 (1.5)	14.2 (1.5)	14.4 (1.4)
HCC development within 5 years: n (%)*	62 (6.2%)	36 (6.0%)	10 (2.0%)

Data expressed as mean (standard deviation) unless otherwise indicated.

AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; HCC, hepatocellular carcinoma; SVR, sustained virological response.

*Data expressed as number of patients (percentage).

whose cutoff value was 3.75 g/dl in patients with a higher platelet count ($\geq 150 \times 10^9/L$). The HCC development rate was 6.3% when albumin levels were lower (< 3.75 g/dl) and 1.5% when levels were higher (≥ 3.75 g/dl). The cutoff value for albumin levels was 4.0 g/dl in patients with a lower platelet count ($< 150 \times 10^9/L$). The HCC development rate was 20.9% when albumin levels were lower (< 4.0 g/dl) and 6.4% when levels were higher (≥ 4.0 g/dl). The fourth and final predictor was AST levels. The HCC development rate was 7.3% when AST levels were at least 40 IU/L and 0% when the levels were < 40 IU/L. On the basis of this analysis, seven subgroups with a 5-year HCC development rate of 0–20.9% were identified. The area under the receiver operating characteristic curve according to the HCC risk prediction model was 0.817.

External validation of the HCC risk prediction model with an independent external cohort

Six hundred nonSVR patients from an external cohort were fitted into the HCC risk prediction model and classified into the seven subgroups. The 5-year HCC development rate of these subgroups was 0–17.9%. The HCC development rate in the individual subgroups of the model derivation group was closely correlated to that in the corresponding subgroups of the external validation group (Fig. 2; correlation coefficient $r^2 = 0.981$). The HCC development rate in the subgroup of patients with the highest risk of HCC development (high-risk group) according to the model older age (≥ 60 years) with a lower platelet count ($< 150 \times 10^9/L$) and lower albumin levels (< 4.0 g/dl) was 20.9% in the model derivation

group and 17.9% in the external validation group. The intermediate-risk group or the patients with an HCC development rate of at least 5% consisted of the following three subgroups: (1) older age (≥ 60 years), lower platelet count ($< 150 \times 10^9/L$), higher albumin levels (≥ 4.0 g/dl), and higher AST levels (≥ 40 IU/L); (2) older age (≥ 60 years), higher platelet count ($\geq 150 \times 10^9/L$), and lower albumin levels (< 3.75 g/dl); and (3) younger age (< 60 years) and lower platelet count ($< 150 \times 10^9/L$). In these intermediate-risk groups, the 5-year HCC development rate was 6.3–7.3% in the model derivation group and 5.3–7.9% in the external validation group. The low-risk group consisted of the following three subgroups: (1) younger age (< 60 years) and higher platelet count ($\geq 150 \times 10^9/L$); (2) older age (≥ 60 years), lower platelet count ($< 150 \times 10^9/L$), higher albumin levels (≥ 4.0 g/dl), and lower AST levels (< 40 IU/L); and (3) older age (≥ 60 years), higher platelet count ($\geq 150 \times 10^9/L$), and higher albumin levels (≥ 3.75 g/dl). In these low-risk groups, the 5-year HCC development rate was 0–1.5% in the model derivation group and 0–2.9% in the external validation group.

Predictability of the HCC risk prediction model on HCC development rate beyond 5 years

Cumulative HCC development rates in the high-, intermediate-, and low-risk groups were compared over time using the Kaplan–Meier method. The 10-year rates were 28.9% in the high-risk group, 22.9% in the intermediate-risk group, and 4.8% in the low-risk group (Fig. 3A). The high and intermediate-risk group created by pooling data from the high- and intermediate-risk groups had a significantly higher cumulative HCC development rate than the low-risk group beyond 5 years (Fig. 3B; 5-year rate, 11.6% vs. 1.0%; 10-year rate, 24.5% vs. 4.8%; $p < 0.0001$).

Effect of response to PEG-IFN plus RBV therapy in the reduction of HCC development: analysis stratified by the HCC risk prediction model

The 600 nonSVR patients and 472 SVR patients in the external cohort were fitted into the HCC risk prediction model and

Table 2. Multivariable analysis of factors associated with subsequent development of HCC within 5 years.

	Odds ratio	95% CI	p value
Age	1.086	1.029-1.146	0.003
Albumin	0.248	0.100-0.613	0.003
Platelet	0.842	0.769-0.921	< 0.0001

CI, confidence interval.




Fig. 1. The decision tree model of HCC development within 5 years. Boxes indicate the factors used to differentiate patients and the cutoff values for those different groups. Pie charts indicate the HCC development rate within 5 years for each group of patients after differentiation. Terminal groups of patients differentiated by analysis are numbered from 1 to 7.

classified into the high- and intermediate-risk group or the low-risk group, as defined above. The HCC development rate was significantly lower in SVR patients than in nonSVR patients in the high- and intermediate-risk group (5-year HCC rate, 9.5% vs. 4.5%; $p = 0.040$, log-rank test). In the low-risk group, the 5-year rate was 1.8% in nonSVR patients and 0.9% in SVR patients. Both rates were low and not significantly different ($p = 0.331$, log-rank test) (Fig. 4).

Discussion

An awareness of the risk of HCC development in the context of routine care for chronic hepatitis C is essential for formulating

an HCC surveillance plan personalized for individual patients. The risk of developing HCC from chronic hepatitis is lower than that from cirrhosis [7]; therefore, across-the-board surveillance for chronic hepatitis C is not recommended [3]. A method to easily determine this risk, without performing serial liver biopsies, would be extremely significant clinically. In the present study, an HCC risk prediction model that included the factors such as age, platelet count, albumin levels, and AST levels was constructed. The model was found to have excellent reproducibility when validated with an external cohort. This model could identify subgroups of chronic hepatitis C patients at high risk of HCC development; the 5-year HCC development rate for the high- and intermediate-risk groups was 11.6%, yielding an annual incidence of 2.3%. This HCC risk prediction model requires only

Research Article




Fig. 2. External validation of the decision tree model with an independent cohort. Each patient in the external validation group was allocated to groups 1–7 following the flowchart of the decision tree. The HCC development rates were then calculated for each group and the graph plotted. The x-axis represents the HCC development rate in the model derivation group, and the y-axis represents the HCC development rate in the external validation group. The HCC development rates in each subgroup of patients are closely correlated between the model derivation group and the external validation group (correlation coefficient: $R^2 = 0.981$).

simple test values that are readily obtained in routine care and can therefore be easily used at the patient bedside. The model can be used to identify patients with a high risk of HCC development and therefore requiring surveillance, thereby allowing the formulation of surveillance plans personalized for individual patients.

Advanced fibrosis has been reported as independent risk factors for HCC development [7,8]. Platelet counts and albumin levels, which were factors selected for discrimination of the risk of HCC development, are closely related to the stage of fibrosis. Their correlation with the HCC risk has been repeatedly demonstrated [9–11,29–31]. The present study confirmed the impact of old age and advanced fibrosis, as reflected by low platelet counts and albumin levels. These results are consistent with our previous report [32]. What is unique to the present study was the study design to build a simple and reliable model for




Fig. 3. Cumulative incidence of HCC development beyond 5 years in subgroups of patients defined by the decision tree model. Cumulative incidences of HCC in the groups classified by the decision tree model are compared. (A) The cumulative HCC development rate beyond 5 years is higher in the high- (group 1) and intermediate-risk (groups 2–4) groups compared to the low-risk group (groups 5–7). (B) The high- and intermediate-risk group created by pooling data from the high- and intermediate-risk groups has a significantly higher cumulative HCC development rate than the low-risk group (5-year rate, 11.6% vs. 1.0%; 10-year rate, 24.5% vs. 4.8%; $p < 0.0001$).




Fig. 4. Sustained virological response to PEG-IFN plus RBV therapy reduces the incidence of HCC development after stratification by the HCC risk. The 600 nonSVR patients and the 472 SVR patients in the external cohort were fitted into the HCC risk prediction model and classified into the high and intermediate-risk group or the low-risk group. The HCC development rate is significantly lower in SVR patients than in nonSVR patients in the high and intermediate-risk group (groups 1–4) (5-year HCC rate, 9.5% vs. 4.5%; $p = 0.040$). In the low-risk group (groups 5–7), the 5-year rate is 1.8% in nonSVR patients and 0.9% in SVR patients. Both rates are low and not significantly different ($p = 0.331$).

the prediction of HCC development that could be easily used in the clinic. For this purpose, a novel statistical method was used, histological factors were excluded in the analysis, the model derivation cohort was restricted to those who had nonSVR and had a long follow-up period duration (5 years), and the reproducibility of the model was independently validated by an external cohort. These are the major differences of the present study compared to our previous report. Many researchers have put a lot of efforts to formulate regression models for HCC prediction [9,10,33]. These prediction models are useful for identifying high-risk patients but are somewhat complicated to use at the bedside because they require calculations to be performed. Our prediction model is used simply by incorporating patients' data obtained through simple tests into the decision tree and following the flowchart. These prediction models based on factors easily accessible in routine clinical settings help physicians identify high-risk patients out of chronic hepatitis.

Viral eradication is the short-term goal of IFN therapy, but the ultimate goal is the prevention of HCC occurrence. Previous reports have shown that SVR to IFN therapy suppresses HCC occurrence in patients with type C liver cirrhosis and chronic hepatitis [7,12,30,34,35]. However, there is a marked heterogeneity in the magnitude of the treatment effect on the risk of HCC among studies, probably due to differences in the baseline risk of HCC among different trials [12]. Thus, the question remains whether the preventive effect of IFN therapy on HCC development could apply to all patients with chronic hepatitis C, especially those without liver cirrhosis. The result of the present study indicated that among high- and intermediate-risk patients, as assessed with our HCC risk prediction model, the cumulative HCC development rate was significantly reduced in SVR patients compared with nonSVR patients. This finding suggests that patients with chronic hepatitis, in whom disease has not yet progressed to hepatic cirrhosis but who are at a high risk of HCC development, benefit from antiviral treatment. The preventive effect of IFN on HCC development was not evident in low-risk patients within 5 years of observation. A longer observation term may be required to analyze the possible effect of antiviral therapy in these patients. Application of the present model on treatment decision may have limitations in that effect to prevent HCC development may differ in newer therapeutic agents such as protease

inhibitors [36,37], and that low-risk patients may also benefit from therapy after a longer term observation period such as 15–20 years.

Patients with chronic hepatitis often have no subjective symptoms accompanying their disease and therefore have a low consciousness of the disease. The broad array of adverse reactions and the high cost of IFN therapy are frequent hurdles in motivating patients to undergo therapy. However, patients may be convinced to undergo therapy or remain motivated for continued therapy if they are made aware of their risk of HCC development and the preventive effect of IFN on HCC development.

In conclusion, a reproducible HCC risk prediction model, which includes the factors such as age, platelet count, albumin levels, and AST levels, was constructed to predict the 5-year HCC development rate in patients with chronic hepatitis C. The model requires only a combination of readily available test values and can therefore be easily used at the bedside. The information provided by the model allows the physician to identify patients requiring IFN therapy for the prevention of HCC and formulate plans for imaging HCC surveillance.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Financial support

This study was supported by a Grant-in-Aid from the Ministry of Health, Labor and Welfare, Japan (H20-kanen-006).

References

[1] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74–108.

[2] Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004;127:S5–S16.

[3] Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005;42:1208–1236.

[4] Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* 1997;112:463–472.

[5] Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. *Hepatology* 1998;28:1687–1695.

[6] Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut* 2000;47:131–136.

[7] Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. *Gut* 2004;53:425–430.

[8] Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, et al. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. *Hepatology* 2010;40:870–877.

[9] Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. *Hepatology* 2003;37:520–527.

[10] Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology* 2009;136:138–148.

[11] Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giully N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *J Hepatol* 2010;52:652–657.

[12] Craxi A, Camma C. Prevention of hepatocellular carcinoma. *Clin Liver Dis* 2005;9:329–346, viii.

[13] Breiman LJH, Friedman RA, Olshen CJ, Stone CM. Classification and regression trees. Calif: Wadsworth; 1980.

[14] Garzotto M, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, et al. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. *Cancer* 2005;104:1911–1917.

[15] Miyaki K, Takei I, Watanabe K, Nakashima H, Omae K. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. *J Epidemiol* 2002;12:243–248.

[16] Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: implications on the future of cancer staging. *Surgery* 2002;132:589–602.

[17] Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German dermatological society. *J Clin Oncol* 2004;22:3660–3667.

[18] Valera VA, Walter BA, Yokoyama N, Koyama Y, Iiai T, Okamoto H, et al. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. *Ann Surg Oncol* 2007;14:34–40.

[19] Zlobec I, Steele R, Nigam N, Compton CC. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. *Clin Cancer Res* 2005;11:5440–5443.

[20] Baquerizo A, Anselmo D, Shackleton C, Chen TW, Cao C, Weaver M, et al. Phosphorus as an early predictive factor in patients with acute liver failure. *Transplantation* 2003;75:2007–2014.

[21] Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. *Hepatology* 2010;40:251–260.

[22] Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, et al. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. *J Med Virol* 2011;83:445–452.

[23] Izumi N, Asahina Y, Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. *Hepat Res Treat* 2010;2010:703602.

[24] Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, et al. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. *J Gastroenterol* 2011;46:401–409.

[25] Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. *J Hepatol* 2011;54:439–448.

[26] Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, et al. Age and total ribavirin dose is an independent predictor of relapse among early virological responders to peg-interferon plus ribavirin therapy in chronic hepatitis C revealed by data mining analysis. *Antivir Ther*, in press.

[27] Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, et al. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. *J Gastroenterol* 2011;46:1111–1119.

[28] LeBlanc M, Crowley J. A review of tree-based prognostic models. *Cancer Treat Res* 1995;75:113–124.

[29] Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. *Cancer* 2006;107:2212–2222.

[30] Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegna L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *Hepatology* 2007;45:579–587.

[31] Bonis PA, Tong MJ, Blatt LM, Conrad A, Griffith JL. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. *Am J Gastroenterol* 1999;94:1605–1612.

Research Article

- [32] Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. *Hepatology* 2010;52:518–527.
- [33] Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. *Hepatology* 1996;23:1112–1118.
- [34] Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet* 1995;346:1051–1055.
- [35] Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. *Ann Intern Med* 2005;142:105–114.
- [36] Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009;360:1839–1850.
- [37] McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009;360:1827–1838.

Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C

N. Tamaki, M. Kurosaki, K. Tanaka, Y. Suzuki, Y. Hoshioka, T. Kato, Y. Yasui, T. Hosokawa, K. Ueda, K. Tsuchiya, H. Nakanishi, J. Itakura, Y. Asahina and N. Izumi *Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan*

Received February 2012; accepted for publication May 2012

SUMMARY. The FIB-4 index is a simple formula to predict liver fibrosis based on the standard biochemical values (AST, ALT and platelet count) and age. We here investigated the utility of the index for noninvasive prediction of progression in liver fibrosis. The time-course alteration in the liver fibrosis stage between paired liver biopsies and the FIB-4 index was examined in 314 patients with chronic hepatitis C. The average interval between liver biopsies was 4.9 years. The cases that showed a time-course improvement in the fibrosis stage exhibited a decrease in the FIB-4 index, and those that showed deterioration in the fibrosis stage exhibited an increase in the FIB-4 index with a significant correlation ($P < 0.001$). Increase in the Δ FIB-4 index per year was an independent predictive factor for the progression in

liver fibrosis with an odds ratio of 3.90 ($P = 0.03$). The area under the receiver operating characteristic curve of the Δ FIB-4 index/year for the prediction of advancement to cirrhosis was 0.910. Using a cut-off value of the Δ FIB-4 index/year <0.4 or ≥ 0.4 , the cumulative incidence of fibrosis progression to cirrhosis at 5 and 10 years was 34% and 59%, respectively in patients with the Δ FIB-4 index/year ≥ 0.4 , whereas it was 0% and 3% in those with the Δ FIB-4 index/year <0.4 ($P < 0.001$). In conclusion, measurement of the time-course changes in the FIB-4 index is useful for the noninvasive and real-time estimation of the progression in liver fibrosis.

Keywords: FIB-4, fibrosis, HCV, noninvasive.

INTRODUCTION

Advanced stage of liver fibrosis in chronic hepatitis C is associated with failure of interferon therapy or development of major concomitant disease such as variceal bleeding, liver failure and hepatocellular carcinoma [1–3]. Therefore, evaluation of the stage of liver fibrosis is essential in clinical practice. Liver biopsy is the gold standard for diagnosis of liver fibrosis [4,5], but inaccuracy in evaluation of fibrosis because of sampling errors [6–8] or by the inter-observer variation has been reported [9]. Real-time assessment of liver fibrosis may be clinically useful, but the invasiveness of liver biopsy precludes repeated examinations.

A variety of noninvasive methods to diagnose liver fibrosis have been proposed. Recently, transient elastography [10–13] and real-time tissue elastography [14] using ultrasonography

have been developed, but these modalities are not widely available. For blood tests, the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio [15], the AST/platelet ratio index (APRI) [16,17] and the Fibrotest [18,19] have been reported to be useful. The FIB-4 index is another prediction value of liver fibrosis in chronic hepatitis C based on the standard biochemical values and age. The FIB-4 index has been reported to be markedly useful for the prediction of advanced liver fibrosis [20,21]. Given its noninvasiveness and simplicity, the FIB-4 index has the advantage of an easy follow-up of the time-course changes by repeated measurements.

In the present study, we investigated the utility of the real-time assessment of the FIB-4 index for the prediction of time-course progression in liver fibrosis.

PATIENTS AND METHODS

Patients

A total of 421 patients with chronic hepatitis C who had repeated liver biopsies between 1991 and 2010 at the Musashino Red Cross hospital were consecutively investigated. All patients received interferon therapy after the first biopsy and had nonsustained virological response. A second

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

Correspondence: Namiki Izumi, MD, Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonancho, Musashino-shi, Tokyo 180-8610, Japan. E-mail: nizumi@musashino.jrc.or.jp

biopsy was performed at least 6 months after the completion of interferon therapy. Exclusion criteria were as follows: (i) co-infection with HBV or HIV ($n = 1$), (ii) alcohol abuse (intake of alcohol equivalent to pure alcohol 40 g/day or more) ($n = 8$), (iii) the presence of nonalcoholic steatohepatitis ($n = 14$), (iv) the presence of hepatocellular carcinoma ($n = 15$), (v) interval between paired biopsies was <1.5 years ($n = 41$) and (vi) length of biopsy sample <15 mm ($n = 28$). The demographic characteristics of the 314 patients enrolled are shown in Table 1.

Assessment of liver fibrosis stage

Liver biopsy was carried out under laparoscopic or ultrasonographic guidance. A sample 15 mm or larger was collected and evaluated. The fibrosis stage was categorized according to the METAVIR score: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. Two pathologists examined all samples and determined the fibrosis stage. When staging was inconsistent between the two pathologists, an appropriate stage was determined by discussion between the two.

Calculation of FIB-4 index

The FIB-4 index at the time of each liver biopsy was calculated based on the blood test results within 1 month before

Table 1 Clinical background of patients

	First biopsy	Second biopsy
Age (years)	53.7 ± 9.8	58.7 ± 9.4
Gender (male/female)	149/165	
AST (IU/L)	64.5 ± 36.7	58.5 ± 37.7
ALT (IU/L)	87.7 ± 58.9	69.9 ± 53.9
Platelet counts ($\times 10^9/L$)	165 ± 48	159 ± 48
Histological findings		
Activity: 0/1/2/3	38/143/117/16	10/147/131/26
Fibrosis: 0-1/2/3/4	139/107/61/7	134/101/63/16
Interval of between biopsies (years)	4.9 ± 2.9	–

AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Table 2 Changes of fibrosis stage over time

Fibrosis stage at first biopsy	Fibrosis stage at second biopsy				Total
	F0-1 (%)	F2 (%)	F3 (%)	F4 (%)	
F0-1	98 (71)	33 (24)	8 (5)	–	139
F2	33 (31)	50 (47)	21 (20)	3 (2)	107
F3	3 (5)	18 (29)	33 (55)	7 (11)	61
F4	–	–	1 (14)	6 (86)	7

liver biopsy according to the following formula: The FIB-4 index = (age [years] \times AST [IU/L]) / (platelet count [$10^9/L$] \times (ALT [IU/L])^{1/2}). Change in the FIB-4 index per year (Δ FIB-4 index/year) was calculated by the following formula: Δ FIB-4 index/year = (the FIB-4 index at the second liver biopsy – the FIB-4 index at the first liver biopsy) / interval between paired biopsies (years). Change in AST, ALT, platelet counts per year (Δ AST/year, Δ ALT/year, Δ Platelet counts/year) and the degree of changes in the fibrosis stage per year were calculated similarly.

Statistical analysis

The SPSS software package 15.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. Categorical data were analysed using Fisher's exact test. Continuous variables were compared with Student's *t*-test. Factors associated with the progression in liver fibrosis were analysed by multivariate logistic regression analysis. Association between progression in fibrosis stage and changes in the FIB-4 was analysed by Spearman's rank correlation test. Kaplan–Meier method and log-rank test were used to analyse time to occurrence of fibrosis progression to cirrhosis. A *P*-value of < 0.05 was considered statistically significant.

RESULTS

Changes in liver fibrosis stage overtime

The clinical backgrounds of patients at the first and second biopsies are shown in Table 1. The average interval was 4.9 years between the two liver biopsies. The fibrosis stage progressed over time in 23%, regressed in 17% and remained unchanged in 60%. Changes of fibrosis stage stratified by the fibrosis stage at the first liver biopsy are shown in Table 2.

Comparison of FIB-4 index and liver fibrosis stage

For the prediction of advanced liver fibrosis (F3–4), a FIB-4 index <1.45 had a negative predictive value of 97%, whereas a FIB-4 > 3.25 had a positive predictive value of 49% at first biopsy. Similarly, a FIB-4 < 1.45 had a negative predictive value of 98%, and a FIB-4 > 3.25 had a positive predictive value of 54% at second biopsy (Fig. 1).




Fig. 1 Comparison of the FIB-4 index and liver fibrosis stage. Patients were categorized into three groups according to the FIB-4 index using cut-off values of < 1.45, 1.45–3.25, > 3.25 at liver biopsy. The lower bar chart (dark grey) indicates patients with F0–2, while the upper bar chart (light grey) indicates patients with F3–4. (a) comparison of the FIB-4 index and liver fibrosis stage at first biopsy and (b) at second biopsy.

Predictive factors for the progression of fibrosis

Higher level of Δ AST/year, lower level of Δ ALT/year, lower level of Δ Platelet counts/year and higher level of the Δ FIB-4/year were significantly associated with the progression of fibrosis overtime (Table 3). Multivariate analysis demonstrated that only the Δ FIB-4 index/year was an independent

predictive factor for the progression of fibrosis stage ($P = 0.03$) with an odds ratio of 3.70 (95% CI:1.07–12.5).

Correlation between the degree of changes in the fibrosis stage and the Δ FIB-4 index per year

When the patients were categorized into five groups according to the degree of changes in the fibrosis stage per year (< -0.2, -0.2 – < 0, 0, > 0 – 0.2 and > 0.2), median value of the Δ FIB-4 index/year was -0.29, -0.02, 0.04, 0.16 and 0.47, respectively. The FIB-4 index reduced along the regression of the fibrosis stage, while the FIB-4 index increased along the progression of the fibrosis stage, which showed a significant correlation ($P < 0.001$) (Fig. 2).

Prediction of progression to cirrhosis by the changes in the FIB-4 index per year

The area under the receiver operating characteristic curve of the Δ FIB-4 index/year for the prediction of advancement to cirrhosis was 0.910. By the Δ FIB-4 index/year of 0.4, the sensitivity and specificity for the prediction of advancement to cirrhosis was 80% and 91%. The cumulative incidence of fibrosis progression to cirrhosis, at 5 and 10 years, was 34% and 59%, respectively, in patients with the Δ FIB-4 index/year ≥ 0.4 , whereas it was 0% and 3% in those with the Δ FIB-4 index/year < 0.4 ($P < 0.001$) (Fig. 3).

DISCUSSION

Recently, noninvasive markers of liver fibrosis have been used as a predictive factor of liver-related outcome such as

Table 3 Factors associated with the progression of liver fibrosis

	Progression of	Nonprogression of	P-value
	Liver fibrosis	Liver fibrosis	
Gender (male/female)	31/42	118/123	0.33
Age at first biopsy (years)	54.4 \pm 8.7	53.5 \pm 10.2	0.50
AST at first biopsy (IU/L)	63.9 \pm 35.0	64.8 \pm 37.3	0.85
ALT at first biopsy (IU/L)	86.5 \pm 58.4	88.1 \pm 59.2	0.84
Platelet counts at first biopsy ($10^9/L$)	15.8 \pm 4.6	16.7 \pm 4.8	0.16
Change between biopsies			
Δ AST (IU/L)/year	3.8 \pm 19.5	-4.1 \pm 14.8	<0.001
Δ ALT (IU/L)/year	-1.9 \pm 28.4	7.2 \pm 22.6	0.005
Δ Platelet counts ($10^9/L$)/year	-4.1 \pm 9.5	-0.002 \pm 9.5	0.001
Δ FIB-4 index/year	0.31 \pm 0.52	-0.005 \pm 0.37	<0.001

Δ AST/year: (AST at the second liver biopsy – AST at the first liver biopsy) /interval between paired biopsies (years); Δ ALT/year: (ALT at the second liver biopsy – ALT at the first liver biopsy) /interval between paired biopsies (years); Δ Platelet counts/year: (platelet counts at the second liver biopsy –platelet counts at the first liver biopsy) /interval between paired biopsies (years); Δ FIB-4 index /year: (the FIB-4 index at the second liver biopsy – the FIB-4 index at the first liver biopsy) /interval between paired biopsies (years).




Fig. 2 Correlation between the degree of changes in the fibrosis stage and the Δ FIB-4 index per year. Boxplot of the Δ FIB-4 index/year is shown according to the degree of changes in the fibrosis stage per year. The bottom and top of each box represent the 25 and 75th percentiles, giving the interquartile range. The line through the box indicates the median value, and the error bar indicates the 5 and 95th percentiles.




Fig. 3 Cumulative incidence of fibrosis progression to cirrhosis. Patients were categorized into two groups according to the Δ FIB-4 index/year using cut-off value of < 0.4 or ≥ 0.4 .

mortality [22–24] or HCC development [24–26] in patients with chronic liver disease. There have been few studies that investigated the association between changes of noninvasive markers and liver-related outcome [27–29]. However, it is still unclear whether there is a relation between the time-course changes in the value of noninvasive markers and progression of liver fibrosis.

The aim of the study was to evaluate the utility of the real-time assessment of the FIB-4 index for the prediction of time-course progression in liver fibrosis. We have shown that the FIB-4 index reduced along the regression of the fibrosis stage, while the FIB-4 index increased along the progression of the fibrosis stage. These results indicate that the measurement of the time-course changes in the FIB-4 index may

be useful for the noninvasive and real-time estimation of the progression in liver fibrosis overtime.

Although the gold standard for diagnosis of liver fibrosis is liver biopsy, there are a variety of problems including invasiveness and sampling errors [6]. Diagnostic methods of liver fibrosis by measurement of elasticity of the liver by ultrasonography [10–14] have been developed, but these modalities are not widely available.

The FIB-4 index has an advantage among these noninvasive liver fibrosis diagnostic methods. Firstly, it is quite easily calculated. The parameters required for calculation are only age, AST, ALT and platelet counts, which are measured at the routine examination of patients with liver disease. Therefore, additional blood collection is unnecessary, and the index can be calculated at no cost. Secondly, because of its simple calculation, it is possible to evaluate the clinical conditions in a real-time manner. Repeated measurements of the FIB-4 index make it possible to predict deterioration in liver fibrosis continuously over time. Because no special equipment or system is necessary, and objective data on the clinical conditions are provided in a real-time manner, the FIB-4 index is simple and convenient compared with other noninvasive liver fibrosis diagnostic methods.

It is widely known that a decrease in platelet counts is useful for the prediction of the progression of fibrosis stage [30]. We have reported that elevated AST or ALT is also associated with the progression of liver fibrosis [31]. However, the results of this study showed that a change in the FIB-4 index over time was a more useful factor for the prediction of the progression of fibrosis stage than AST, ALT and changes in platelet counts.

Liver biopsy is still an important examination as the gold standard for diagnosis of liver fibrosis, but time-course changes cannot be readily observed by repeated biopsies because of its invasiveness. On the other hand, it is possible to estimate the progression of liver fibrosis by repeated measurement of the FIB-4 index. Therefore, two examinations should be combined: liver biopsy may be utilized to determine the baseline of fibrosis stage, and the serial measurement of the FIB-4 index may be utilized to predict changes of fibrosis stages overtime in a real-time manner.

In conclusion, we believe that measurement of the time-course changes in the FIB-4 index is useful for the noninvasive and real-time estimation of the progression in liver fibrosis.

ACKNOWLEDGEMENTS

This study was supported by a grant-in-aid from Ministry of Health, Labor and Welfare, Japan.

CONFLICT OF INTEREST

No conflicts of interest exist for all authors.

REFERENCES

- 1 Dienstag JL. The role of liver biopsy in chronic hepatitis C. *Hepatology* 2002; 5(Suppl 1): S152–S160.
- 2 Benvegna L, Gios M, Boccatto S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. *Gut* 2004; 53(5): 744–749.
- 3 Serfaty L, Aumaitre H, Chazouilleres O *et al.* Determinants of outcome of compensated hepatitis C virus-related cirrhosis. *Hepatology* 1998; 27(5): 1435–1440.
- 4 Gebo KA, Herlong HF, Torbenson MS *et al.* Role of liver biopsy in management of chronic hepatitis C: a systematic review. *Hepatology* 2002; 5(Suppl 1): S161–S172.
- 5 Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. *Hepatology* 2001; 33(1): 196–200.
- 6 Bravo AA, Sheth SG, Chopra S. Liver biopsy. *N Engl J Med* 2001; 344(7): 495–500.
- 7 Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 2003; 38(6): 1449–1457.
- 8 Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. *J Hepatol* 2003; 39(2): 239–244.
- 9 The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 1994; 20(1 Pt 1): 15–20.
- 10 Sandrin L, Fourquet B, Hasquenoph JM *et al.* Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003; 29(12): 1705–1713.
- 11 Ganne-Carrie N, Ziolk M, de Ledinghen V *et al.* Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. *Hepatology* 2006; 44(6): 1511–1517.
- 12 Foucher J, Chanteloup E, Vergniol J *et al.* Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut* 2006; 55(3): 403–408.
- 13 Castera L, Vergniol J, Foucher J *et al.* Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005; 128(2): 343–350.
- 14 Tatsumi C, Kudo M, Ueshima K *et al.* Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography. *Intervirology* 2008; 51(Suppl 1): 27–33.
- 15 Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. *Gastroenterology* 1988; 95(3): 734–739.
- 16 Wai CT, Greenston JK, Fontana RJ *et al.* A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; 38(2): 518–526.
- 17 Lin ZH, Xin YN, Dong QJ *et al.* Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology* 2011; 53(3): 726–736.
- 18 Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001; 357(9262): 1069–1075.
- 19 Sebastiani G, Vario A, Guido M *et al.* Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. *J Hepatol* 2006; 44(4): 686–693.
- 20 Sterling RK, Lissen E, Clumeck N *et al.* Development of a simple non-invasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; 43(6): 1317–1325.
- 21 Vallet-Pichard A, Mallet V, Nalpas B *et al.* FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. *Hepatology* 2007; 46(1): 32–36.
- 22 Vergniol J, Foucher J, Terreboune E *et al.* Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. *Gastroenterology* 2011; 140(7): 1970–1979. 1979 e1971–1973.
- 23 Nunes D, Fleming C, Offner G *et al.* Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. *Am J Gastroenterol* 2010; 105(6): 1346–1353.
- 24 Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. *J Viral Hepat* 2011; 18(10): 738–744.
- 25 Masuzaki R, Tateishi R, Yoshida H *et al.* Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. *Hepatology* 2009; 49(6): 1954–1961.
- 26 Jung KS, Kim SU, Ahn SH *et al.* Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). *Hepatology* 2011; 53(3): 885–894.
- 27 Vergniol J, Foucher J, Castera L *et al.* Changes of non-invasive markers and FibroScan values during HCV treatment. *J Viral Hepat* 2009; 16(2): 132–140.
- 28 Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. *World J Gastroenterol* 2010; 16(45): 5710–5715.
- 29 Jain MK, Seremba E, Bhoire R *et al.* Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. *AIDS Patient Care STDS* 2012; 26(2): 73–80.
- 30 Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. *J Viral Hepat* 1997; 4(3): 199–208.
- 31 Kurosaki M, Matsunaga K, Hirayama I *et al.* The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. *J Hepatol* 2008; 48(5): 736–742.

Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy

Takanori Hosokawa, Masayuki Kurosaki, Kaoru Tsuchiya, Shuya Matsuda, Masaru Muraoka, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Toru Nakata, Takashi Nishimura, Shoko Suzuki, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Namiki Izumi

Takanori Hosokawa, Masayuki Kurosaki, Kaoru Tsuchiya, Shuya Matsuda, Masaru Muraoka, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Toru Nakata, Takashi Nishimura, Shoko Suzuki, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Namiki Izumi, Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan

Author contributions: Hosokawa T and Kurosaki M contributed equally to this work; Kurosaki M and Izumi N made substantial contributions to the conception and design of the study; Tsuchiya K, Matsuda S, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Nakata T, Nishimura T, Suzuki S, Ueda K, Nakanishi H, Itakura J, Takahashi Y and Izumi N collected the clinical data; Hosokawa T and Kurosaki M contributed to the analysis and interpretation of the data; Hosokawa T wrote the draft of the manuscript; Kurosaki M and Izumi N made critical revisions of the manuscript; and Izumi N obtained a research fund.

Supported by A Grant-in-Aid from the Ministry of Health, Labor and Welfare, Japan

Correspondence to: Namiki Izumi, MD, Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610,

Japan. nizumi@musashino.jrc.or.jp

Telephone: +81-422-323111 Fax: +81-422-329551

Received: June 17, 2012 Revised: September 6, 2012

Accepted: October 16, 2012

Published online: January 14, 2013

Abstract

AIM: To evaluate whether metabolic factors are related to distant recurrence of hepatocellular carcinoma (HCC) and survival after curative treatment.

METHODS: This retrospective study included 344 patients whose HCC was treated curatively by radiofrequency ablation (RFA) therapy. The mean age was 67.6 years and the mean observation period was 4.04 years. The etiological background of liver disease was

hepatitis B virus infection in 30, hepatitis C virus infection in 278, excessive alcohol drinking in 9, and other in 27 patients. The Child-Pugh classification grade was A ($n = 307$) or B ($n = 37$). The number of HCC nodules was one in 260, two in 61, and three in 23 patients. For surveillance of HCC recurrence after curative therapy with RFA, patients were radiologically evaluated every 3 mo. Factors associated with distant recurrence of HCC or survival were studied.

RESULTS: Inadequate maintenance of blood glucose in diabetic patients was associated with higher incidence of distant recurrence. The 1-, 2-, and 3-year recurrence rates were significantly higher in diabetic patients with inadequate maintenance of blood glucose compared with the others: 50.6% vs 26.8%, 83.5% vs 54.4%, and 93.8% vs 73.0%, respectively ($P = 0.0001$). Inadequate maintenance of blood glucose was an independent predictor of distant recurrence [adjusted relative risk 1.97 (95%CI, 1.33-2.91), ($P = 0.0007$)] after adjustment for other risk factors, such as number of HCC nodules [2.03 (95%CI, 1.51-2.73), $P < 0.0001$] and initial level of serum alpha fetoprotein (AFP) [1.43 (95%CI, 1.04-1.97), $P = 0.028$]. Obesity was not an independent predictor of recurrence. The incidence of distant recurrence did not differ between diabetic patients with adequate maintenance of blood glucose and non-diabetic patients. Among 232 patients who had HCC recurrence, 138 had a second recurrence. The 1-, 2-, and 3-year rates of second recurrence were significantly higher in diabetic patients with inadequate maintenance of blood glucose than in the others: 9.0% vs 5.9%, 53.1% vs 24.3%, and 69.6% vs 42.3%, respectively ($P = 0.0021$). Inadequate maintenance of blood glucose in diabetic patients [1.99 (95%CI, 1.23-3.22), $P = 0.0049$] and presence of multiple HCC nodules [1.53 (95%CI, 1.06-2.22), $P = 0.024$] were again significantly associated with second HCC recurrence. Inadequate maintenance of blood glucose in diabetic

patients was also a significant predictor of poor survival [2.77 (95%CI, 1.38-5.57), $P = 0.0046$] independent of excessive alcohol drinking [6.34 (95%CI, 1.35-29.7), $P = 0.019$], initial level of serum AFP [3.40 (95%CI, 1.88-6.18), $P < 0.0001$] and Child-Pugh classification grade B [2.24 (95%CI, 1.12-4.46), $P = 0.022$]. Comparing diabetic patients with inadequate maintenance of blood glucose *vs* the others, the 1-, 2-, and 3-year survival rates were significantly lower in diabetic patients with inadequate maintenance of blood glucose: 92% *vs* 99%, 85% *vs* 96%, and 70% *vs* 92%, respectively ($P = 0.0003$).

CONCLUSION: Inadequate maintenance of blood glucose in diabetic patients is a significant risk factor for recurrence of HCC and for poor survival after curative RFA therapy.

© 2013 Baishideng. All rights reserved.

Key words: Hyperglycemia; Hepatocellular carcinoma; Recurrence; Radio frequency ablation; Survival

Hosokawa T, Kurosaki M, Tsuchiya K, Matsuda S, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Nakata T, Nishimura T, Suzuki S, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. *World J Gastroenterol* 2013; 19(2): 249-257 Available from: URL: <http://www.wjg-net.com/1007-9327/full/v19/i2/249.htm> DOI: <http://dx.doi.org/10.3748/wjg.v19.i2.249>

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide^[1] and its incidence has been increasing in many countries^[2]. Surgical resection, liver transplantation, and local ablation therapy, such as radiofrequency ablation (RFA) therapy, have been considered as efficient curative therapies for HCC. RFA therapy is now widely performed in patients with small HCC^[3] and a randomized controlled study demonstrated that the survival rates were similar in patients with small HCC receiving RFA or surgical resection^[4]. A characteristic of HCC is its high rate of recurrence after curative resection or local ablation therapy, reaching approximately 80% within 5 years^[5-7]. Identification of factors related to recurrence of HCC and therapeutic intervention targeting these factors may lead to prevention of frequent recurrence of HCC and improved survival.

Tumor factors, such as the number of HCC nodules and their size, are associated with the recurrence of HCC and survival prognosis^[8-10]. Another factor that is associated with the recurrence of HCC and survival is the hepatic reserve function at the time of HCC therapy^[8,10,11]. Hepatitis C virus (HCV) and hepatitis B virus (HBV) infection are the major causes responsible for 80% of HCC cases^[2] and antiviral therapy targeting HCV^[12,13] or

HBV^[14] has been shown to decrease HCC recurrence, and improve hepatic reserve function and survival. Non-alcoholic steatohepatitis (NASH) has also received attention as a cause of HCC^[15]. Metabolic factors, such as obesity and diabetes, are closely linked to the etiology of NASH. These metabolic factors have also been identified as risk factors for several other types of cancer. Obesity is associated with increased mortality rates of several cancers^[16,17] and diabetes is also reported as a risk factor for liver, pancreatic, renal, and colon cancers^[18,19]. If these metabolic factors are related to the recurrence of HCC, therapeutic intervention targeting these factors may lead to prevention of frequent recurrence of HCC and improved survival. The impact of diabetes on the recurrence of HCC after treatment has been discussed, but with conflicting results^[20-23].

In this study, factors contributing to the recurrence and prognosis of HCC after curative treatment were analyzed. We found that inadequate maintenance of blood glucose was related to the high rate of HCC recurrence and poor survival.

MATERIALS AND METHODS

Patients whose HCC was treated by RFA at the Musashino Red Cross Hospital were studied retrospectively for factors associated with recurrence of HCC and survival. The inclusion criteria were as follows: (1) HCC treated curatively with RFA at the Musashino Red Cross Hospital between 1999 and 2007; (2) maximum diameter of HCC nodule ≤ 3 cm; (3) number of HCC nodules ≤ 3 ; (4) no previous history of treatment for HCC; and (5) follow-up observation for at least 6 mo after RFA therapy. 344 patients met these criteria, including 140 women and 204 men, with a mean age of 67.6 years and mean observation time of 4.04 years. The clinical characteristics of the patients are summarized in Table 1. The etiological background of liver disease was HBV infection in 30, HCV infection in 278, excessive alcohol drinking (intake of ethanol ≥ 60 g/d for ≥ 5 years continuously) in 9, and non-B non-C non-alcoholic etiology in 27 patients. The Child-Pugh classification grade was either A ($n = 307$) or B ($n = 37$). The number of HCC nodules was one in 260, two in 61, and three in 23 patients. Thus, 260 patients had a single lesion, and 84 had multiple lesions. The maximum diameter of HCC nodules was 19.9 ± 0.3 mm.

Obesity was defined as a body mass index > 25 kg/m² according to the definition of the Japan Society for the Study of Obesity^[24]. Blood glucose was measured monthly for 6 mo after HCC treatment and the average value was determined. Inadequate maintenance of blood glucose was defined as an average value of blood glucose ≥ 200 mg/dL. The level of hemoglobin A1c (HbA1c) was not used in the present study because the lifespan of erythrocytes is shortened due to hypersplenism in patients with chronic hepatitis or cirrhosis, leading to lower HbA1c levels relative to the blood glucose level^[25]. Diagnosis of type 2 diabetes was made according to the

Table 1 Characteristics of patients undergoing curative radiofrequency ablation for hepatocellular carcinoma *n* (%)

Variable	Value
Sex (male/female)	204/140
Age(yr)	67.6 ± 8.4
Etiology of liver disease: HBV/HCV/NBNC	30/278/36
AST (IU/L)	84.0 ± 34.5
ALT (IU/L)	73.2 ± 36.5
GGT (IU/L)	82.9 ± 96.8
T-Chol (mg/dL)	157.8 ± 32.0
TG (mg/dL)	112.3 ± 55.7
Mean blood sugar (mg/dL)	139.3 ± 44.0
Diabetes mellitus	159 (48)
BMI > 25 kg/m ²	86 (25)
Maximum diameter of HCC nodule (mm)	19.9 ± 0.3
Number of HCC nodules: single/2 or 3	260/84
AFP (ng/mL)	214 ± 1025
Alcohol drinking > 60 g/d	9 (2.6)
Child-Pugh grade: A/B	307/37

HBV: Hepatitis B virus; HCV: Hepatitis C virus; NBNC: Neither HBV nor HCV; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ -glutamyltransferase; T-Chol: Total cholesterol; TG: Triglyceride; BMI: Body mass index; AFP: α -fetoprotein; HCC: Hepatocellular carcinoma.

American Diabetes Association criteria of a fasting blood glucose level ≥ 126 mg/dL (≥ 7.0 mmol/L) and/or HbA1c level ≥ 6.5 ^[26]. After initial treatment of HCC by RFA, the ablated area was confirmed by contrast-enhanced computed tomography (CT) within one week. If the ablated area was not sufficient, then RFA therapy was repeated until the HCC nodule was completely ablated.

HCC surveillance and diagnosis of recurrence

Diagnosis of HCC was based on abdominal ultrasonography, contrast-enhanced CT, magnetic resonance imaging (MRI), or angiography. Classical HCC was diagnosed for tumors showing vascular enhancement with washout on at least two types of diagnostic imaging. Tumor biopsy was used to diagnose tumors with non-classical imaging findings.

For surveillance of HCC recurrence after curative therapy with RFA, patients were evaluated by abdominal ultrasonography, contrast-enhanced CT, or contrast-enhanced MRI every three months. Recurrence of HCC was diagnosed based on a new lesion detected by ultrasonography showing vascular enhancement with washout on CT or MRI. If the tumor was not hypervascular, a tumor biopsy was performed to confirm the diagnosis.

Statistical analysis

For analysis of survival and recurrence, the time of initial RFA treatment was defined as day zero. Survival rate and recurrence rate were analyzed by the Kaplan-Meier method and log rank test. Multivariate analysis was performed using a Cox proportional hazard model. Data were analyzed using StatView Version 5.0 (SAS Institute Inc, Cary, North Carolina, United States) and IBM-SPSS statistics version 18 (IBM SPSS Inc, Chicago, IL, United States). Statistical significance was set at $P < 0.05$.

RESULTS

Factors associated with HCC recurrence

Of the 344 patients whose HCC was curatively treated by RFA, 232 had HCC recurrence. The 1-, 2-, and 3-year recurrence rates were 29.3%, 57.5%, and 75.2%, respectively. On univariate analysis, inadequate maintenance of blood glucose, higher initial level of serum AFP and multiple HCC nodules were significantly associated with HCC recurrence. Obesity ($P = 0.06$) and diabetes ($P = 0.65$) were not significantly associated with HCC recurrence.

Thirty-seven patients had diabetes with inadequate maintenance of blood glucose, 122 patients had diabetes with adequate maintenance of blood glucose, and 185 patients did not have diabetes. The HCC recurrence rate was significantly higher in diabetic patients with inadequate maintenance of blood glucose than in the others ($P = 0.0001$) (Figure 1A).

Comparing patients with diabetes ($n = 159$) and patients who did not have diabetes ($n = 185$), there was no significant difference in the recurrence rate ($P = 0.65$). Upon comparison of the three groups, i.e., the diabetes with inadequate maintenance of blood glucose group, the diabetes with adequate maintenance of blood glucose group, and the non-diabetes group, the recurrence rate was significantly higher in the diabetes with inadequate maintenance of blood glucose group than in the other two groups ($P = 0.0001$) (Figure 1B). On the other hand, there was no significant difference in the HCC recurrence rate between the diabetes patients with adequate maintenance of blood glucose group and the non-diabetes group.

In terms of the number of HCC nodules, namely, single ($n = 260$) *vs* multiple ($n = 84$), the recurrence rate was significantly higher in patients with multiple HCC nodules ($P = 0.0001$). Within each subgroup of patients with single and multiple HCC nodules, diabetes with inadequate maintenance of blood glucose was significantly associated with recurrence of HCC (single, $P = 0.006$; multiple, $P = 0.025$) (Figure 2A, B). In terms of the initial level of serum AFP ≥ 100 ng/mL ($n = 70$) *vs* < 100 ng/mL ($n = 274$), the recurrence rate was significantly higher in patients with AFP ≥ 100 ng/mL ($P = 0.018$). Within each subgroup of patients with AFP ≥ 100 ng/mL and < 100 ng/mL, diabetes with inadequate maintenance of blood glucose was associated with a higher rate of recurrence (AFP ≥ 100 ng/mL, $P = 0.005$; AFP < 100 ng/mL, $P = 0.017$) (Figure 2C, D).

Independent risk factors for distant recurrence of HCC on multivariate analysis were inadequate maintenance of blood glucose in diabetic patients [adjusted relative risk, 1.97 (95%CI, 1.33-2.91), $P = 0.0007$], multiple HCC nodules [2.03 (1.51-2.73), $P < 0.0001$], and AFP ≥ 100 ng/mL [1.43 (1.04-1.97), $P = 0.028$] (Table 2).

Factors associated with second recurrence

Among the 232 patients who had HCC recurrence, 138 had a second recurrence. Regarding second recurrence, inadequate maintenance of blood glucose in diabetic pa-




Figure 1 Kaplan-Meier curves showing a higher rate of hepatocellular carcinoma recurrence in diabetic patients with hyperglycemia. A: The cumulative incidence of the recurrence of hepatocellular carcinoma (HCC) was significantly higher in diabetic patients with inadequate maintenance of blood glucose (blood glucose ≥ 200 mg/dL solid line) than in the others (dotted line) ($P = 0.0001$); B: The HCC recurrence rate was significantly higher in diabetic patients with inadequate maintenance of blood glucose (solid line) than in diabetic patients with adequate maintenance of blood glucose (blood glucose < 200 mg/dL, broken line) or non-diabetic patients (dotted line) ($P = 0.0001$). There was no significant difference in HCC recurrence rate between diabetic patients with adequate maintenance of blood glucose and non-diabetic patients.

Table 2 Multivariate analysis of factors associated with recurrence of hepatocellular carcinoma

Factors	Odds ratio (95%CI)	P-value
First recurrence		
Inadequate maintenance of blood glucose	1.97 (1.33-2.91)	0.0007
Multiple HCC nodules	2.03 (1.51-2.73)	< 0.0001
AFP ≥ 100 ng/mL	1.43 (1.04-1.97)	0.028
Second recurrence		
Inadequate maintenance of blood glucose (mg/dL)	1.99 (1.23-3.22)	0.0049
Multiple HCC nodules	1.53 (1.06-2.22)	0.024

Inadequate maintenance of blood glucose was defined as an average of casual blood glucose of ≥ 200 mg/dL. HCC: Hepatocellular carcinoma; AFP: α -fetoprotein.

tients and multiple HCC nodules were again significantly associated with HCC recurrence. Obesity ($P = 0.18$), diabetes ($P = 0.31$) and initial level of serum AFP ($P = 0.08$) were not associated with second recurrence. In terms of the number of HCC nodules, namely, single *vs* multiple, the 1-, 2-, and 3-year recurrence rates were significantly higher in patients with multiple lesions (6.4% *vs* 6.1%, 39.3% *vs* 23.1%, and 52.5% *vs* 42.3%, respectively, $P = 0.013$). Upon comparing diabetic patients with inadequate maintenance of blood glucose *vs* the others, the rate of second recurrence was significantly higher in diabetic patients with inadequate maintenance of blood glucose ($P = 0.0021$) (Figure 3A). Upon comparing patients with diabetes *vs* patients who did not have diabetes, the rates of second recurrence were not significantly different (P

$= 0.31$). Upon comparison of the three groups, i.e., the diabetes with inadequate maintenance of blood glucose group, the diabetes with adequate maintenance of blood glucose group, and the non-diabetes group, the second recurrence rate was again significantly higher in the diabetes with inadequate maintenance of blood glucose group than in the other two groups ($P = 0.0035$) (Figure 3B). On the other hand, there was no significant difference in the second recurrence rate between the diabetes with adequate maintenance of blood glucose group and the non-diabetes group.

Independent risk factors for second recurrence of HCC on multivariate analysis were inadequate maintenance of blood glucose [1.99 (95%CI, 1.23-3.22), $P = 0.0049$] and multiple HCC nodules [1.53 (95%CI, 1.06-2.22), $P = 0.024$] (Table 2).

Factors associated with survival

There were 52 HCC-related or hepatic failure deaths. On univariate analysis, inadequate maintenance of blood glucose, excessive alcohol drinking, higher initial level of serum AFP and Child-Pugh classification grade B were significantly associated with survival. Obesity ($P = 0.81$) and diabetes ($P = 0.11$) were not significantly associated with survival.

Upon comparing diabetic patients with inadequate maintenance of blood glucose *vs* the others, the survival rate was significantly lower in patients with inadequate maintenance of blood glucose ($P = 0.0003$) (Figure 4A). Upon comparing diabetic patients *vs* non-diabetic patients, the survival rates were not significantly different




Figure 2 Diabetic patients with inadequate maintenance of blood glucose have higher rate of hepatocellular carcinoma recurrence after stratification by other risk factors. A: $P = 0.006$ for single hepatocellular carcinoma (HCC) nodule; B: $P = 0.025$ for multiple HCC nodules; C: $P = 0.005$ for AFP ≥ 100 ng/mL; D: $P = 0.017$ for α -fetoprotein (AFP) < 100 ng/mL. The cumulative incidence of the recurrence of HCC was significantly higher in diabetic patients with inadequate maintenance of blood glucose (solid line) than in the others (dotted line), after stratification by number of HCC nodules and by initial level of AFP.

Table 3 Multivariable analysis of factors associated with survival

Factors	Odds ratio (95%CI)	P-value
Inadequate maintenance of blood glucose	2.77 (1.38-5.57)	0.0046
Alcohol drinking ≥ 60 g/d	6.34 (1.35-29.7)	0.019
Child Pugh grade B	2.24 (1.12-4.46)	0.022
AFP ≥ 100 ng/mL	3.40 (1.88-6.18)	< 0.0001

Inadequate maintenance of blood glucose was defined as an average of casual blood glucose of ≥ 200 mg/dL. AFP: α -fetoprotein.

($P = 0.11$). of the survival rate was compared among the three groups, i.e., the diabetes with inadequate maintenance of blood glucose group, the diabetes with adequate maintenance of blood glucose group, and the non-diabetes group. The survival rate was significantly poorer in the diabetes with inadequate maintenance of blood glucose group than in the other two groups ($P = 0.0003$) (Figure 4B), while it did not differ between the diabetes with adequate maintenance of blood glucose group and the non-diabetes group.

The number of HCC nodules, which was a significant factor for HCC recurrence, was not related to survival ($P = 0.34$). Patients with excessive alcohol drinking had poor survival prognosis compared to those with non-excessive or no alcohol drinking ($P = 0.046$). Survival was

better in patients in Child-Pugh A class than in patients in Child-Pugh B class ($P = 0.0082$). AFP ≥ 100 ng/mL was associated with poor survival compared with AFP < 100 ng/mL ($P < 0.0001$).

On multivariate analysis, inadequate maintenance of blood glucose was a significant predictor of poor survival [2.77 (95%CI, 1.38-5.57), $P = 0.0046$] independent of excessive alcohol drinking [6.34 (95%CI, 1.35-29.7), $P = 0.019$], initial level of serum AFP ≥ 100 ng/mL [3.40 (95%CI, 1.88-6.18), $P < 0.0001$] and Child-Pugh classification grade B [2.24 (95%CI, 1.12-4.46), $P = 0.022$] (Table 3).

DISCUSSION

The impact of metabolic factors, such as hyperglycemia, diabetes and obesity, on distant recurrence and survival after curative RFA therapy for HCC was analyzed retrospectively. We identified that inadequate maintenance of blood glucose in diabetic patients was a significant and independent risk factor for early recurrence of HCC and a risk factor for poor survival, whereas obesity and diabetes were not. Diabetic patients with inadequate maintenance of blood glucose had a higher rate of HCC recurrence and poorer survival compared with diabetic patients with adequate maintenance of blood glucose and non-diabetic patients. In other words, even in patients with diabetes, if




Figure 3 Kaplan-Meier curves showing a higher rate of second recurrence of hepatocellular carcinoma in diabetic patients with inadequate maintenance of blood glucose. A: The cumulative incidence of the second recurrence of hepatocellular carcinoma (HCC) was significantly higher in diabetic patients with inadequate maintenance of blood glucose (blood glucose ≥ 200 mg/dL solid line) than in the others (dotted line) ($P = 0.002$); B: The rate of second recurrence of HCC was significantly higher in diabetic patients with inadequate maintenance of blood glucose (solid line) than in diabetic patients with adequate maintenance of blood glucose (blood glucose < 200 mg/dL, broken line) or non-diabetic patients (dotted line) ($P = 0.004$). There was no significant difference in the rate of second recurrence of HCC between diabetic patients with adequate maintenance of blood glucose and non-diabetic patients.

the blood glucose was adequately maintained, the HCC recurrence rate and survival did not differ significantly compared with those in non-diabetic patients. These results indicate the possibility that adequate management of hyperglycemia may lead to reduction in the risk of HCC recurrence and improvement of overall survival.

The contribution of diabetes to the development of HCC has been confirmed in several reports^[27-30]. The impact of diabetes on the recurrence of HCC after treatment has also been discussed, but with conflicting results^[20-22]. A recent study from Taiwan demonstrated that diabetes may not affect the intra-hepatic HCC recurrence and survival after RFA^[23]. The results of the present study also indicated that diabetes itself is not a significant risk factor if the level of blood glucose is adequately managed. Rather, hyperglycemia was a significant risk factor for the recurrence of HCC. There may be several mechanisms involved in the relationship between hyperglycemia and HCC recurrence. Hyperglycemia promotes cancer cell proliferation in pancreatic cancer cells and breast cancer cells^[31-33] through accelerated cell cycle progression or through the production of reactive oxygen species, leading to activation of protein kinase C and increased DNA synthesis in cancer cells^[34]. A previous study in hepatitis C patients indicated that hyperglycemia after challenge with 75-g oral glucose tolerance test was associated with the risk for HCC while hyperglycemia at fasting was not^[35]. A possible reason for this result may be that patients with post-challenge hyperglycemia may have higher fluctuations in daily glucose levels that lead to oxidative stress^[35], because it was reported that acute fluctuations in blood glucose levels cause greater oxidative stress than

sustained chronic hyperglycemia^[36]. Taken together, a possible mechanism for the relationship between higher level of casual blood glucose and development of HCC in the present study may be that daily fluctuations in serum glucose levels caused greater oxidative stress. Alternatively, hyper-insulinemia or increased level of insulin-like growth factor, which are caused by hyperglycemia, may be related to carcinogenesis^[37-39]. Insulin levels were not measured in our study; therefore, the effects of insulin could not be identified.

Discussions are now taking place on methods of treating diabetes from the standpoint of cancer prevention. Control of hyperglycemia could reduce cancer incidence, which means that hyperglycemia could directly contribute to the development of cancer^[39]. The results of our study also showed that adequate management of hyperglycemia may lead to reduction in the risk of HCC recurrence and improvement of overall survival. Improvement in insulin resistance is undoubtedly the most important factor for the treatment of diabetes, but glycemic control is often difficult to achieve with dietary therapy, exercise, or insulin resistance-improving drugs alone. It was reported that metformin may be associated with a lower risk of cancer^[38] and there is a theoretical concern that exogenous insulin may be associated with an increased risk of cancer^[40]. In fact, a recent study reported that insulin therapy in patients with HCV infection is linked with the development of HCC^[41]. On the other hand, with insulin treatment, concomitant use of metformin has been reported to offset the carcinogenic risk of insulin^[42]. Whether glycemic control should be a priority, or whether avoiding hyper-insulinemia because




Figure 4 Patients with inadequate maintenance of blood glucose have a lower survival rate. A: The survival rate after curative local ablation therapy for hepatocellular carcinoma (HCC) was significantly lower in diabetic patients with inadequate maintenance of blood glucose (blood glucose ≥ 200 mg/dL solid line) than in the others (dotted line) ($P = 0.0003$); B: The survival rate was significantly lower in diabetic patients with inadequate maintenance of blood glucose (solid line) than in diabetic patients with adequate maintenance of blood glucose (blood glucose < 200 mg/dL, broken line) or non-diabetic patients (dotted line) ($P = 0.0003$). There was no significant difference in survival rate between diabetic patients with adequate maintenance of blood glucose and non-diabetic patients.

of therapy should be a priority, is an issue for future investigation.

In terms of survival of HCC patients, associations with liver function and tumor factors have been reported^[10], but conflicting results have been reported for the relationship with diabetes^[20,21]. These two studies involved heterogeneous groups of HCC patients treated with various therapies, including surgery, local ablation therapy and transcatheter arterial embolization. This heterogeneity may have led to the conflicting results, because the survival of HCC patients may be strongly affected by the initial treatment. Our study involved a homogeneous patient population, i.e., all patients were initially treated curatively by RFA. The results of our study suggest that glycemic control in diabetic patients, more so than diabetes itself, plays a role in survival. The mechanism by which glycemic control and survival are related is unknown, but frequent recurrence of HCC in hyperglycemic patients and the accumulation of damage in liver function because of repeated treatment intervention for HCC may lead to worsening survival.

In conclusion, inadequate maintenance of blood glucose in diabetic patients was a significant and independent risk factor for early recurrence of HCC and for poor survival. Adequate management of hyperglycemia in diabetic patients may lead to reduction in the risk of HCC recurrence and improvement in overall survival.

COMMENTS

Background

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Radiofrequency ablation (RFA) therapy is an efficient curative therapy

for HCC, but long-term survival is limited because of the high rate of distant recurrence of approximately 80% within 5 years. Identification of factors related to recurrence of HCC and therapeutic intervention targeting these factors may lead to prevention of frequent recurrence of HCC and improved survival.

Research frontiers

Metabolic factors, such as obesity and diabetes, have been identified as risk factors for several types of cancer, such as cancer of the liver, pancreas, kidney, and colon. These metabolic factors may be related to recurrence of HCC. The impact of diabetes on the recurrence of HCC after treatment has been discussed, but with conflicting results.

Innovations and breakthroughs

The authors identified that inadequate maintenance of blood glucose in diabetic patients was a significant and independent risk factor for early recurrence of HCC and a risk factor for poor survival, whereas diabetes was not. In other words, even in patients with diabetes, if the blood glucose was adequately maintained, then the HCC recurrence rate and survival did not differ significantly from those in non-diabetic patients.

Applications

The results of the present study indicate the possibility that adequate management of hyperglycemia in diabetic patients may lead to reduction in the risk of HCC recurrence and improvement of overall survival.

Peer review

This is an important study in which the effect of inadequate maintenance of blood glucose in diabetes has been shown as a significant risk factor for distant recurrence of hepatocellular carcinoma and poor survival after curative radiofrequency ablation therapy.

REFERENCES

- 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; **55**: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
- 2 Bosch FX, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004; **127**: S5-S16 [PMID: 15508102 DOI: 10.1053/j.gastro.2004.09.011]
- 3 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M.

- Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). *Hepatol Res* 2010; **40**: 667-685 [PMID: 20633193 DOI: 10.1111/j.1872-034X.2010.00673.x]
- 4 **Chen MS**, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006; **243**: 321-328 [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8]
 - 5 **Tateishi R**, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. *Cancer* 2005; **103**: 1201-1209 [PMID: 15690326 DOI: 10.1002/cncr.20892]
 - 6 **Izumi N**, Asahina Y, Noguchi O, Uchihara M, Kanazawa N, Itakura J, Himeno Y, Miyake S, Sakai T, Enomoto N. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. *Cancer* 2001; **91**: 949-956 [PMID: 11251946]
 - 7 **Curley SA**, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. *Ann Surg* 2000; **232**: 381-391 [PMID: 10973388 DOI: 10.1097/0000658-200009000-00010]
 - 8 **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. *Ann Surg* 1999; **229**: 216-222 [PMID: 10024103 DOI: 10.1097/0000658-199902000-00009]
 - 9 **Tung-Ping Poon R**, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. *Ann Surg* 2000; **232**: 10-24 [PMID: 10862190 DOI: 10.1097/0000658-200007000-00003]
 - 10 **Kudo M**, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. *Hepatology* 2004; **40**: 1396-1405 [PMID: 15565571 DOI: 10.1002/hep.20486]
 - 11 **Fuke H**, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Yoneda K, Yamamoto N, Ito K, Takaki H, Nakatsuka A, Yamakado K, Takeda K, Takei Y. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. *Aliment Pharmacol Ther* 2008; **27**: 1253-1260 [PMID: 18221404 DOI: 10.1111/j.1365-2036.2008.03627.x]
 - 12 **Hagihara H**, Nouse K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. *Int J Clin Oncol* 2011; **16**: 210-220 [PMID: 21152943 DOI: 10.1007/s10147-010-0150-x]
 - 13 **Miyake Y**, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. *J Viral Hepat* 2010; **17**: 287-292 [PMID: 19732321 DOI: 10.1111/j.1365-2893.2009.01181.x]
 - 14 **Wong JS**, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, Wong J, Lee KF, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. *Aliment Pharmacol Ther* 2011; **33**: 1104-1112 [PMID: 21488914 DOI: 10.1111/j.1365-2036.2011.04634.x]
 - 15 **Bugianesi E**, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology* 2002; **123**: 134-140 [PMID: 12105842 DOI: 10.1016/S1590-8658(02)90208-2]
 - 16 **Calle EE**, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003; **348**: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]
 - 17 **Renahan AG**, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008; **371**: 569-578 [PMID: 18280327 DOI: 10.1016/S0140-6736(08)60269-X]
 - 18 **Inoue M**, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. *Arch Intern Med* 2006; **166**: 1871-1877 [PMID: 17000944]
 - 19 **Hu FB**, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. *J Natl Cancer Inst* 1999; **91**: 542-547 [PMID: 10088625 DOI: 10.1093/jnci/91.6.542]
 - 20 **Toyoda H**, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriya S, Tanikawa M, Sone Y, Hisanaga Y. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. *Cancer* 2001; **91**: 957-963 [PMID: 11251947]
 - 21 **Huo TI**, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, Chang FY, Lee SD. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. *Am J Gastroenterol* 2004; **99**: 1479-1487 [PMID: 15307864 DOI: 10.1111/j.1572-0241.2004.30024.x]
 - 22 **Komura T**, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. *Am J Gastroenterol* 2007; **102**: 1939-1946 [PMID: 17573788 DOI: 10.1111/j.1572-0241.2007.01354.x]
 - 23 **Chen WT**, Macatula TC, Lin CC, Lin CJ, Lin SM. Diabetes may not affect outcomes in hepatocellular carcinoma after radio-frequency ablation. *Hepatogastroenterology* 2011; **58**: 551-557 [PMID: 21661430]
 - 24 **Youkou A**, Hasegawa T, Suzuki K, Koya T, Sakagami T, Toyabe S, Arakawa M, Gejyo F, Narita I, Suzuki E. Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity. *Intern Med* 2011; **50**: 1911-1916 [PMID: 21921368 DOI: 10.2169/internalmedicine.50.5474]
 - 25 **Aizawa N**, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki E, Shimomura S, Iijima H, Nakamura H, Nishiguchi S. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. *World J Hepatol* 2012; **4**: 11-17 [PMID: 22312451 DOI: 10.5754/hge12064]
 - 26 **American Diabetes Association**. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010; **33** Suppl 1: S62-S69 [PMID: 20042775]
 - 27 **Davila JA**, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. *Gut* 2005; **54**: 533-539 [PMID: 15753540 DOI: 10.1136/gut.2004.052167]
 - 28 **Lai MS**, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. *Hepatology* 2006; **43**: 1295-1302 [PMID: 16729295 DOI: 10.1002/hep.21208]
 - 29 **El-Serag HB**, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol* 2006; **4**: 369-380 [PMID: 16527702 DOI: 10.1016/j.cgh.2005.12.007]
 - 30 **Hassan MM**, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis